Saxenda May Continue to Lead in the Diabetes Segment in 2018

In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64% in local currencies. According to IQVIA, by the end of November 2017, Saxenda accounted for 79%, 86%, 72%, 52%, 47%, 40%, 30%, 19%, 14%, and 6% of the total value of anti-obesity medications sold in the United Arab Emirates, Canada, Denmark, the United States, Italy, Spain, Brazil, Germany, Australia, and Mexico, respectively. In December 2017, Novo Nordisk submitted an application to the FDA seeking an update to Saxenda’s label to include data from the LEADER trial.